Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating yesterday.
David Risinger has given his Buy rating due to a combination of factors, including the strategic positioning of Eli Lilly & Co in the global pharmaceutical market. Despite the challenges posed by tariffs, the company is committed to maintaining its research and development efforts, which are crucial for future growth and innovation.
Additionally, Eli Lilly’s investment in international facilities, such as the new $800 million facility in Ireland, demonstrates its commitment to expanding its global footprint and production capabilities. This strategic expansion is likely to enhance the company’s competitive edge and support its long-term growth prospects.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $1,190.00 price target.
Based on the recent corporate insider activity of 140 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.